Literature DB >> 33867672

Primary hyperparathyroidism in a child with abdominal pain and hematuria.

Yuta Fukaya1, Yuji Oto1, Takeshi Inoue1, Hisashi Itabashi1, Masahisa Shiraishi1, Akihisa Nitta1, Nobuyuki Murakami1, Shigehiro Soh2, Toshihisa Ogawa3, Tomoyo Matsubara1.   

Abstract

Entities:  

Keywords:  adolescents; hypercalcemia; multiple endocrine neoplasia; primary hyperparathyroidism; urolithiasis

Year:  2021        PMID: 33867672      PMCID: PMC8022038          DOI: 10.1297/cpe.30.111

Source DB:  PubMed          Journal:  Clin Pediatr Endocrinol        ISSN: 0918-5739


× No keyword cloud information.

Introduction

Primary hyperparathyroidism (PHPT) is an endocrine disease characterized by chronically elevated serum calcium and abnormally high PTH levels (1). Disease complications vary considerably, with urolithiasis, fractures, osteoporosis, and hypercalcemia being the most common (1). The symptoms of PHPT in children are non-specific. PHPT is a relatively common disease in the adult population. However, it is rare among children and adolescents. The accurate diagnosis of PHPT in pediatric patients is difficult, often leading to delayed treatment (2). There are few case reports and limited information available on Japanese children with PHPT (3, 4). Here, we described a Japanese child with PHPT who presented with abdominal pain and hematuria.

Case Report

A 12-yr-old girl was referred to our hospital with recurrent abdominal pain and gross hematuria. The patient had no medical or family history of endocrine disorders, including hypercalcemia and endocrine neoplasia. Her abdominal pain was acute, colicky, and felt in the flank. There were no abnormal signs on physical examination. The bilateral flank pain was intermittent, and costovertebral angle tenderness was negative. Computed tomography (CT) revealed bilateral kidney stones. Laboratory evaluation revealed markedly elevated serum calcium (13.7 mg/dl, normal range: 8.8–10.1 mg/dl) and PTH (321 pg/ml, normal range: 10–65 pg/ml) levels, and low phosphorus (2.8 mg/dl, normal range: 2.6–4.6 mg/dl). The urinary calcium-creatinine ratio was 0.36 g/g•Cr (normal: < 0.30). The results of stone analysis showed that calcium phosphate and calcium oxalate accounted for 60% and 40% of kidney stones, respectively. Cervical ultrasonography revealed hyperplasia of the right parathyroid gland (Fig. 1a). Methoxy-2-isobutyl isonitrile (MIBI) scintigraphy showed a focus with MIBI accumulation in the same region (Fig. 1b). Dual-energy X-ray absorptiometry (DEXA) revealed low bone mineral density at the L2–4 vertebrae (Z score: −2.7 SD). Based on these findings, the patient was diagnosed with PHPT. To exclude multiple endocrine neoplasia syndromes (MEN), we evaluated the trunk CT scan and head magnetic resonance imaging and conducted various hormonal tests. No abnormalities were detected. Serum calcitonin and catecholamine levels were within normal limits (Table 1). Accordingly, we diagnosed that the patient’s parathyroid pathology involved a simple parathyroid adenoma and not MEN. Single-gland parathyroidectomy was performed without complications. An enlarged parathyroid gland was located in the lower right portion of the thyroid gland. The weight of the resected tumor was 1,860 mg and measured 25 mm × 24 mm × 13 mm (Fig. 1c). Histological findings revealed a parathyroid adenoma (Fig. 1d). Immediately after surgery, the serum intact PTH level dropped to 10 pg/ml. The patient was provided with calcium supplementation in fluid, and her serum calcium level was 9.3 mg/dl. There were no episodes of hypocalcemia after surgery. The calcium dose was gradually reduced and discontinued after 1 wk. The patient’s abdominal pain or hematuria resolved after surgery. DEXA scan of the bone density in the lumbar spine improved to –1.9 SD after 6 mo and normalized to –1.2 SD after 10 mo.
Fig. 1.

Images of the enlarged right parathyroid gland. a: Cervical ultrasonography revealed hyperplasia of the right parathyroid measuring 22.3 mm and presenting as a low echoic lesion in the posterior part of the right thyroid gland. b: Methoxy-2-isobutyl isonitrile (MIBI) scintigraphy showed a focus with MIBI accumulation in the right parathyroid gland. c: Extracted right parathyroid gland weighing 1,860 mg. (d): Hematoxylin and eosin staining showed the typical architecture of an adenoma.

Table 1.

Laboratory data of the patient

Images of the enlarged right parathyroid gland. a: Cervical ultrasonography revealed hyperplasia of the right parathyroid measuring 22.3 mm and presenting as a low echoic lesion in the posterior part of the right thyroid gland. b: Methoxy-2-isobutyl isonitrile (MIBI) scintigraphy showed a focus with MIBI accumulation in the right parathyroid gland. c: Extracted right parathyroid gland weighing 1,860 mg. (d): Hematoxylin and eosin staining showed the typical architecture of an adenoma.

Discussion

We report a case of PHPT in a Japanese child who presented with urolithiasis. PHPT in children is rare, and limited information is available regarding hyperparathyroidism in children in Japan (3, 4). Children with PHPT have more varied and less specific clinical symptoms than adults with PHPT (2). The characteristic feature of PHPT in children is a delayed presentation. Most adult cases of PHPT are diagnosed by incidental detection of hypercalcemia during routine investigations in asymptomatic patients (1). In contrast, approximately 80% of children with PHPT are symptomatic (5). This delay in diagnosis leads to organ damage, and children with PHPT are usually seriously ill (6). Among children with PHPT, 45% and 17% of patients develop urolithiasis and abdominal pain, respectively (7). Urolithiasis is generally less common in children than in adults and is related to underlying diseases such as genetic diseases, congenital urinary malformations, and endocrinological diseases. The main components of uroliths are calcium phosphate or calcium oxalate in 60% and 40% of stones, respectively (8). Most uroliths in children are composed of calcium oxalate (40–60%) (8). Approximately 3% of adult patients with urolithiasis have PHPT, and 10% of adult patients with PHPT present with recurrent urolithiasis. There is limited information available regarding the association between PHPT and urolithiasis in children. Therefore, PHPT should be included in the differential diagnosis of urolithiasis in children. Genetic syndromes that are associated with multiple abnormal parathyroid glands may account for 5–15% of all cases of PHPT and are more common in patients younger than 40 yr of age than in older patients (9). MEN is the most common cause of inherited PHPT and a syndrome with increased mortality. Early genetic diagnosis and regular follow-up are needed for the timely detection of MEN (10). Clinicians must be aware of the possibility of MEN. In this case, no abnormal findings were detected in the thyroid gland, adrenal gland, or pancreas. Although we did not perform MEN gene testing, long-term follow-up assessments are needed to determine the prognosis. We will perform MEN gene testing if the patient presents with another episode of endocrine neoplasia. In conclusion, we reported a case of PHPT in a Japanese child who presented with urolithiasis. PHPT should be considered in children with urolithiasis, and regular follow-ups are needed because PHPT is the earliest indicator of MEN.

Conflict of interests

The authors declare no conflict of interest.
  10 in total

1.  Differences in primary hyperparathyroidism characteristics between children and adolescents.

Authors:  Vladan Zivaljevic; Milan Jovanovic; Aleksandar Diklic; Vera Zdravkovic; Maja Djordjevic; Ivan Paunovic
Journal:  J Pediatr Surg       Date:  2019-10-25       Impact factor: 2.545

2.  Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism.

Authors:  Lee F Starker; Tobias Akerström; William D Long; Alberto Delgado-Verdugo; Patricia Donovan; Robert Udelsman; Richard P Lifton; Tobias Carling
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

3.  Primary hyperparathyroidism in pediatric patients.

Authors:  Josh Kollars; Abdalla E Zarroug; Jon van Heerden; Aida Lteif; Penny Stavlo; Luis Suarez; Christopher Moir; Michael Ishitani; David Rodeberg
Journal:  Pediatrics       Date:  2005-04       Impact factor: 7.124

4.  Aetiology, Diagnosis and Surgical Treatment of Primary Hyperparathyroidism in Children: New Trends.

Authors:  Swethan Alagaratnam; Tom R Kurzawinski
Journal:  Horm Res Paediatr       Date:  2015-05-01       Impact factor: 2.852

5.  Urinary parameters as predictors of primary hyperparathyroidism in patients with nephrolithiasis.

Authors:  Mathew D Sorensen; Quan-Yun Duh; Raymon H Grogan; Thanh C Tran; Marshall L Stoller
Journal:  J Urol       Date:  2011-12-15       Impact factor: 7.450

Review 6.  Primary hyperparathyroidism in children and adolescents.

Authors:  Jeffrey Roizen; Michael A Levine
Journal:  J Chin Med Assoc       Date:  2012-08-21       Impact factor: 2.743

Review 7.  Primary hyperparathyroidism.

Authors:  Marcella D Walker; Shonni J Silverberg
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

8.  Primary hyperparathyroidism in young people. When should we perform genetic testing for multiple endocrine neoplasia 1 (MEN-1)?

Authors:  T Lassen; L Friis-Hansen; A K Rasmussen; U Knigge; U Feldt-Rasmussen
Journal:  J Clin Endocrinol Metab       Date:  2014-04-14       Impact factor: 5.958

9.  A case of primary hyperparathyroidism in childhood found by a chance hematuria.

Authors:  Yasuhisa Ohata; Takehisa Yamamoto; Yukihiro Kitai; Yoshimi Mizoguchi; Masaru Iwaki; Kiyoaki Sumi; Yasuhiro Fujikawa; Minoru Koga; Hideki Sugao; Tsunesuke Shimotsuji; Keiichi Ozono
Journal:  Clin Pediatr Endocrinol       Date:  2007-02-07

10.  Decrement in bone mineral density after parathyroidectomy in a pediatric patient with primary hyperparathyroidism.

Authors:  Hidechika Morimoto; Hisakazu Nakajima; Jun Mori; Shota Fukuhara; Keiichi Shigehara; Shinsuke Adachi; Hajime Hosoi
Journal:  Clin Pediatr Endocrinol       Date:  2018-04-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.